Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Many Firsts As Celltrion/Pfizer's Inflectra Becomes Second US Biosimilar

This article was originally published in SRA

Executive Summary

Move over Zarxio. There's a new kid in town: Inflectra (infliximab-dyyb) has received approval from the US Food and Drug Administration as the first monoclonal antibody biosimilar licensed in the US1.

You may also be interested in...



Brazil's Limited Legal Framework On Biosimilar Interchangeability Could Actually Help Sponsors

Anvisa currently has no legislative authority to tell the Ministry of Health to refrain from providing biosimilar medications interchangeably, giving drugmakers an expanded opportunity to access Brazil's large patient population.

Brazil's Limited Legal Framework On Biosimilar Interchangeability Could Actually Help Sponsors

Anvisa currently has no legislative authority to tell the Ministry of Health to refrain from providing biosimilar medications interchangeably, giving drugmakers an expanded opportunity to access Brazil's large patient population.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

UsernamePublicRestriction

Register

PS118605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel